β Home
βΉοΈ Info
π§Ύ At a Glance π Core Facts ποΈ Products/Services β Ratings π§βπΌ Executives π¬ My Commentsπ‘ Analytics
π Insights (1) π’ Company Q&A (574) π οΈ Industry Q&A (121) π Competitors π Price Low π Price Swings β‘ SWOT ποΈ PEST π Porter's Five Forces β¨ Score Positive β οΈ Risk Assessment π§© Segmentation π Ά Google Linksπ Ratios
π° Margins π Financial Ratios π± Growth π Enterprise Value π Key Metrics π΅ Dividendsπ§ Tools
β Due Diligenceπ’ Press Releases
| Date | Press release |
|---|---|
| 2026-04-02 06:50:00 | Merck Announces Initiation Of Pivotal Phase 2b/3 Trial Evaluating Mk-8748 (tiespectus), An Investigational Bispecific Tie2 Agonist/vegf Inhibitor, For The Treatment Of Neovascular Age-related Macular Degeneration Rahway, n.j.--(business wire)--merck (nyse: mrk), known as msd outside of the united states and canada, today announced the initiation of a pivotal phase 2b/3 trial evaluating mk-8748 (also known as tiespectus, eye201), a novel investigational bispecific antibody that directly activates tie2 signaling and inhibits vascular endothelial growth factor (vegf), for the treatment of neovascular (wet) age-related macular degeneration (nvamd). the study, known as malbec, is the first trial of a broader. |
| 2026-04-01 07:00:00 | Merck To Hold First-quarter 2026 Sales And Earnings Conference Call April 30 Rahway, n.j.--(business wire)--merck to hold first-quarter 2026 sales and earnings conference call april 30. |
| 2026-03-31 08:00:00 | Infinimmune Enters Collaboration With Merck To Discover Novel Human Antibody Therapeutics Alameda, calif.--(business wire)-- #ai--infinimmune enters collaboration with merck to discover novel human antibody therapeutics. |
| 2026-03-30 11:45:00 | Merckβs Enlicitide Decanoate, An Investigational Oral Pcsk9 Inhibitor, Demonstrated Significantly Greater Ldl-c Reductions At Eight Weeks Compared To Guideline-recommended Oral Non-statin Therapies When Added To Background Statins Rahway, n.j.--(business wire)--enlicitide, an investigational oral pcsk9 inhibitor, demonstrated significantly greater ldl-c reductions compared to oral non-statin therapies. |
| 2026-03-25 21:59:00 | Terns Pharmaceuticals Investor Alert: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Terns Pharmaceuticals, Inc. - Tern New york & new orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (βksfβ) are investigating the proposed sale of terns pharmaceuticals, inc. (nasdaqgs: tern) to merck (nyse: mrk). under the terms of the proposed transaction, shareholders of terns will receive $53.00 in cash for each share of terns that they own. ksf is seeking to determine whether this consideration and the process that led to it are adequate,. |
| 2026-03-25 06:48:00 |
|
| 2026-03-25 06:45:00 |
|
| 2026-03-24 06:00:00 |
|
| 2026-03-18 16:30:00 |
|
| 2026-03-18 08:00:00 |
|
| 2026-03-17 06:50:00 |
|
| 2026-03-16 08:00:00 |
|
| 2026-03-04 08:00:00 |
|
| 2026-02-28 10:05:00 |
|
| 2026-02-28 10:00:00 |
|
π° Browse additional press releases for Merck!
Sign up for free or log inπ Unlock our free guide: "The Checklist Value Investor β A Smarter Way to Pick Stocks"